SALSA: A regulator of the early steps of complement activation on mucosal surfaces

Frontiers in Immunology

Volumn 7, Issue MAR, 2016, Pages

  Reichhardt, Martin Parnov ^a   Meri, Seppo ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

C1q; Crohn's disease; DMBT1; Ficolins; Gp340; IBD; MBL; Ulcerative colitis

Indexed keywords

AGGLUTININ; C REACTIVE PROTEIN; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C4B; FICOLIN; LACTOFERRIN; MANNOSE BINDING LECTIN; MUCIN 5B; PENTRAXIN; PROCOLLAGEN C PROTEINASE; SALIVARY SCAVENGER AND AGGLUTININ PROTEIN; SCAVENGER RECEPTOR; SECRETORY IMMUNOGLOBULIN; SURFACTANT PROTEIN A; SURFACTANT PROTEIN D; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

CANDIDA ALBICANS; COMPLEMENT ACTIVATION; CROHN DISEASE; DENTAL CARIES; ENTERITIS; GENE FREQUENCY; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; INFLAMMATORY BOWEL DISEASE; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUTH MUCOSA; PROTEIN EXPRESSION; PROTEIN INTERACTION; SHORT SURVEY; ZONA PELLUCIDA;

EID: 84964607444     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2016.00085     Document Type: Short Survey

References (71)

1. Boackle RJ. The interaction of salivary secretions with the human complement system - a model for the study of host defense systems on inflamed mucosal surfaces. Crit Rev Oral Biol Med (1991) 2:355-67.
2. Persson CG, Erjefalt I, Alkner U, Baumgarten C, GreiffL, Gustafsson B, et al. Plasma exudation as a first line respiratory mucosal defence. Clin Exp Allergy (1991) 21:17-24. doi: 10.1111/j.1365-2222.1991.tb00799.x.
3. Courts FJ, Boackle RJ, Fudenberg HH, Silverman MS. Detection of functional complement components in gingival crevicular fluid from humans with periodontal diseases. J Dent Res (1977) 56:327-31. doi:10.1177/00220345770560032001.
4. Boackle RJ, Connor MH, Vesely J. High molecular weight non-immunoglobulin salivary agglutinins (NIA) bind C1Q globular heads and have the potential to activate the first complement component. Mol Immunol (1993) 30:309-19. doi:10.1016/0161-5890(93)90059-K.
5. Leito JT, Ligtenberg AJ, van Houdt M, van den Berg TK, Wouters D. The bacteria binding glycoprotein salivary agglutinin (SAG/gp340) activates complement via the lectin pathway. Mol Immunol (2011) 49:185-90. doi:10.1016/j.molimm.2011.08.010.
6. Reichhardt MP, Loimaranta V, Thiel S, Finne J, Meri S, Jarva H. The salivary scavenger and agglutinin binds MBL and regulates the lectin pathway of complement in solution and on surfaces. Front Immunol (2012) 3:205. doi:10.3389/fimmu.2012.00205.
7. Gunput ST, Ligtenberg AJ, Terlouw B, Brouwer M, Veerman EC, Wouters D. Complement activation by salivary agglutinin is secretor status dependent. Biol Chem (2015) 396:35-43. doi:10.1515/hsz-2014-0200.
8. Ericson T, Rundegren J. Characterization of a salivary agglutinin reacting with a serotype c strain of Streptococcus mutans. Eur J Biochem (1983) 133:255-61. doi:10.1111/j.1432-1033.1983.tb07456.x.
9. Holmskov U, Lawson P, Teisner B, Tornoe I, Willis AC, Morgan C, et al. Isolation and characterization of a new member of the scavenger receptor superfamily, glycoprotein-340 (gp-340), as a lung surfactant protein-D binding molecule. J Biol Chem (1997) 272:13743-9. doi:10.1074/jbc.272.21.13743.
10. Mollenhauer J, Wiemann S, Scheurlen W, Korn B, Hayashi Y, Wilgenbus KK, et al. DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3-26.1 is deleted in malignant brain tumours. Nat Genet (1997) 17:32-9. doi:10.1038/ng0997-32.
11. Kang W, Reid KB. DMBT1, a regulator of mucosal homeostasis through the linking of mucosal defense and regeneration? FEBS Lett (2003) 540:21-5. doi:10.1016/S0014-5793(03)00217-5.
12. Ligtenberg AJ, Veerman EC, Nieuw Amerongen AV, Mollenhauer J. Salivary agglutinin/glycoprotein-340/DMBT1: a single molecule with variable composition and with different functions in infection, inflammation and cancer. Biol Chem (2007) 388:1275-89. doi:10.1515/BC.2007.158.
13. Madsen J, Mollenhauer J, Holmskov U. Review: gp-340/DMBT1 in mucosal innate immunity. Innate Immun (2010) 16:160-7. doi:10.1177/1753425910368447.
14. Thornton DJ, Davies JR, Kirkham S, Gautrey A, Khan N, Richardson PS, et al. Identification of a nonmucin glycoprotein (gp-340) from a purified respiratory mucin preparation: evidence for an association involving the MUC5B mucin. Glycobiology (2001) 11:969-77. doi:10.1093/glycob/11.11.969.
15. Rundegren J, Arnold RR. Differentiation and interaction of secretory immunoglobulin A and a calcium-dependent parotid agglutinin for several bacterial strains. Infect Immun (1987) 55:288-92.
16. Tino MJ, Wright JR. Glycoprotein-340 binds surfactant protein-A (SP-A) and stimulates alveolar macrophage migration in an SP-A-independent manner. Am J Respir Cell Mol Biol (1999) 20:759-68. doi:10.1165/ajrcmb.20.4.3439.
17. Thim L, Mortz E. Isolation and characterization of putative trefoil peptide receptors. Regul Pept (2000) 90:61-8. doi:10.1016/S0167-0115(00)00110-5.
18. Oho T, Bikker FJ, Nieuw Amerongen AV, Groenink J. A peptide domain of bovine milk lactoferrin inhibits the interaction between streptococcal surface protein antigen and a salivary agglutinin peptide domain. Infect Immun (2004) 72:6181-4. doi:10.1128/IAI.72.10.6181-6184.2004.
19. Muller H, Renner M, Helmke BM, End C, Weiss C, Poeschl J, et al. Deleted in malignant brain tumors 1 is up-regulated in bacterial endocarditis and binds to components of vegetations. J Thorac Cardiovasc Surg (2009) 138:725-32. doi:10.1016/j.jtcvs.2009.05.021.
20. Mitoma M, Oho T, Shimazaki Y, Koga T. Inhibitory effect of bovine milk lactoferrin on the interaction between a streptococcal surface protein antigen and human salivary agglutinin. J Biol Chem (2001) 276:18060-5. doi:10.1074/jbc. M101459200.
21. End C, Bikker F, Renner M, Bergmann G, Lyer S, Blaich S, et al. DMBT1 functions as pattern-recognition molecule for poly-sulfated and poly-phosphorylated ligands. Eur J Immunol (2009) 39:833-42. doi:10.1002/eji.200838689.
22. Wickstrom C, Christersson C, Davies JR, Carlstedt I. Macromolecular organization of saliva: identification of 'insoluble' MUC5B assemblies and non-mucin proteins in the gel phase. Biochem J (2000) 351(Pt 2):421-8. doi:10.1042/bj3510421.
23. Loimaranta V, Jakubovics NS, Hytonen J, Finne J, Jenkinson HF, Stromberg N. Fluid- or surface-phase human salivary scavenger protein gp340 exposes different bacterial recognition properties. Infect Immun (2005) 73:2245-52. doi:10.1128/IAI.73.4.2245-2252.2005.
24. Prakobphol A, Xu F, Hoang VM, Larsson T, Bergstrom J, Johansson I, et al. Salivary agglutinin, which binds Streptococcus mutans and Helicobacter pylori, is the lung scavenger receptor cysteine-rich protein gp-340. J Biol Chem (2000) 275:39860-6. doi:10.1074/jbc. M006928200.
25. Madsen J, Tornoe I, Nielsen O, Lausen M, Krebs I, Mollenhauer J, et al. CRP-ductin, the mouse homologue of gp-340/deleted in malignant brain tumors 1 (DMBT1), binds Gram-positive and Gram-negative bacteria and interacts with lung surfactant protein D. Eur J Immunol (2003) 33:2327-36. doi:10.1002/eji.200323972.
26. Haukioja A, Loimaranta V, Tenovuo J. Probiotic bacteria affect the composition of salivary pellicle and streptococcal adhesion in vitro. Oral Microbiol Immunol (2008) 23:336-43. doi:10.1111/j.1399-302X.2008.00435.x.
27. Rosenstiel P, Sina C, End C, Renner M, Lyer S, Till A, et al. Regulation of DMBT1 via NOD2 and TLR4 in intestinal epithelial cells modulates bacterial recognition and invasion. J Immunol (2007) 178:8203-11. doi:10.4049/jimmunol.178.12.8203.
28. Jumblatt MM, Imbert Y, Young WW Jr, Foulks GN, Steele PS, Demuth DR. Glycoprotein 340 in normal human ocular surface tissues and tear film. Infect Immun (2006) 74:4058-63. doi:10.1128/IAI.01951-05.
29. Nagashunmugam T, Malamud D, Davis C, Abrams WR, Friedman HM. Human submandibular saliva inhibits human immunodeficiency virus type 1 infection by displacing envelope glycoprotein gp120 from the virus. J Infect Dis (1998) 178:1635-41. doi:10.1086/314511.
30. Hartshorn KL, White MR, Mogues T, Ligtenberg T, Crouch E, Holmskov U. Lung and salivary scavenger receptor glycoprotein-340 contribute to the host defense against influenza A viruses. Am J Physiol Lung Cell Mol Physiol (2003) 285:L1066-76. doi:10.1152/ajplung.00057.2003.
31. Holmskov U, Mollenhauer J, Madsen J, Vitved L, Gronlund J, Tornoe I, et al. Cloning of gp-340, a putative opsonin receptor for lung surfactant protein D. Proc Natl Acad Sci U S A (1999) 96:10794-9. doi:10.1073/pnas.96.19.10794.
32. Mollenhauer J, Herbertz S, Holmskov U, Tolnay M, Krebs I, Merlo A, et al. DMBT1 encodes a protein involved in the immune defense and in epithelial differentiation and is highly unstable in cancer. Cancer Res (2000) 60:1704-10.
33. Mollenhauer J, Herbertz S, Helmke B, Kollender G, Krebs I, Madsen J, et al. Deleted in malignant brain tumors 1 is a versatile mucin-like molecule likely to play a differential role in digestive tract cancer. Cancer Res (2001) 61:8880-6.
34. Kang W, Nielsen O, Fenger C, Madsen J, Hansen S, Tornoe I, et al. The scavenger receptor, cysteine-rich domain-containing molecule gp-340 is differentially regulated in epithelial cell lines by phorbol ester. Clin Exp Immunol (2002) 130:449-58. doi:10.1046/j.1365-2249.2002.01992.x.
35. Stoddard E, Cannon G, Ni H, Kariko K, Capodici J, Malamud D, et al. gp340 expressed on human genital epithelia binds HIV-1 envelope protein and facilitates viral transmission. J Immunol (2007) 179:3126-32. doi:10.4049/jimmunol.179.5.3126.
36. Schulz BL, Oxley D, Packer NH, Karlsson NG. Identification of two highly sialylated human tear-fluid DMBT1 isoforms: the major high-molecular-mass glycoproteins in human tears. Biochem J (2002) 366:511-20. doi:10.1042/bj20011876.
37. Reichhardt MP, Jarva H, de Been M, Rodriguez JM, Jimenez Quintana E, Loimaranta V, et al. The salivary scavenger and agglutinin in early life: diverse roles in amniotic fluid and in the infant intestine. J Immunol (2014) 193:5240-8. doi:10.4049/jimmunol.1401631.
38. Sonesson M, Ericson D, Kinnby B, Wickstrom C. Glycoprotein 340 and sialic acid in minor-gland and whole saliva of children, adolescents, and adults. Eur J Oral Sci (2011) 119:435-40. doi:10.1111/j.1600-0722.2011.00879.x.
39. Ligtenberg AJ, Karlsson NG, Veerman EC. Deleted in malignant brain tumors-1 protein (DMBT1): a pattern recognition receptor with multiple binding sites. Int J Mol Sci (2010) 11:5212-33. doi:10.3390/ijms1112521.
40. Wu Z, Van Ryk D, Davis C, Abrams WR, Chaiken I, Magnani J, et al. Salivary agglutinin inhibits HIV type 1 infectivity through interaction with viral glycoprotein 120. AIDS Res Hum Retroviruses (2003) 19:201-9. doi:10.1089/088922203763315704.
41. Jonasson A, Eriksson C, Jenkinson HF, Kallestal C, Johansson I, Stromberg N. Innate immunity glycoprotein gp-340 variants may modulate human susceptibility to dental caries. BMC Infect Dis (2007) 7:57. doi:10.1186/1471-2334-7-57.
42. Mollenhauer J, Holmskov U, Wiemann S, Krebs I, Herbertz S, Madsen J, et al. The genomic structure of the DMBT1 gene: evidence for a region with susceptibility to genomic instability. Oncogene (1999) 18:6233-40. doi:10.1038/sj.onc.1203071.
43. Mollenhauer J, Muller H, Kollender G, Lyer S, Diedrichs L, Helmke B, et al. The SRCR/SID region of DMBT1 defines a complex multi-allele system representing the major basis for its variability in cancer. Genes Chromosomes Cancer (2002) 35:242-55. doi:10.1002/gcc.10115.
44. Mollenhauer J, Helmke B, Muller H, Kollender G, Lyer S, Diedrichs L, et al. Sequential changes of the DMBT1 expression and location in normal lung tissue and lung carcinomas. Genes Chromosomes Cancer (2002) 35:164-9. doi:10.1002/gcc.10096.
45. Ligtenberg AJ, Veerman EC, Nieuw Amerongen AV. A role for Lewis a antigens on salivary agglutinin in binding to Streptococcus mutans. Antonie Van Leeuwenhoek (2000) 77:21-30. doi:10.1023/A:1002054810170.
46. Eriksson C, Frangsmyr L, Danielsson Niemi L, Loimaranta V, Holmskov U, Bergman T, et al. Variant size- and glycoforms of the scavenger receptor cysteine-rich protein gp-340 with differential bacterial aggregation. Glycoconj J (2007) 24:131-42. doi:10.1007/s10719-006-9020-1.
47. Reid KB, Porter RR. Subunit composition and structure of subcomponent C1q of the first component of human complement. Biochem J (1976) 155:19-23. doi:10.1042/bj1550019.
48. Sellar GC, Blake DJ, Reid KB. Characterization and organization of the genes encoding the A-, B- and C-chains of human complement subcomponent C1q. The complete derived amino acid sequence of human C1q. Biochem J (1991) 274(Pt 2):481-90. doi:10.1042/bj2740481.
49. Kojouharova MS, Tsacheva IG, Tchorbadjieva MI, Reid KB, Kishore U. Localization of ligand-binding sites on human C1q globular head region using recombinant globular head fragments and single-chain antibodies. Biochim Biophys Acta (2003) 1652:64-74. doi:10.1016/j.bbapap.2003.08.003.
50. Ligtenberg AJ, Bikker FJ, De Blieck-Hogervorst JM, Veerman EC, Nieuw Amerongen AV. Binding of salivary agglutinin to IgA. Biochem J (2004) 383:159-64. doi:10.1042/BJ20040265.
51. White MR, Crouch E, Vesona J, Tacken PJ, Batenburg JJ, Leth-Larsen R, et al. Respiratory innate immune proteins differentially modulate the neutrophil respiratory burst response to influenza A virus. Am J Physiol Lung Cell Mol Physiol (2005) 289:L606-16. doi:10.1152/ajplung.00130.2005.
52. White MR, Crouch E, van Eijk M, Hartshorn M, Pemberton L, Tornoe I, et al. Cooperative anti-influenza activities of respiratory innate immune proteins and neuraminidase inhibitor. Am J Physiol Lung Cell Mol Physiol (2005) 288:L831-40. doi:10.1152/ajplung.00365.2004.
53. Jarva H, Jokiranta TS, Hellwage J, Zipfel PF, Meri S. Regulation of complement activation by C-reactive protein: targeting the complement inhibitory activity of factor H by an interaction with short consensus repeat domains 7 and 8-11. J Immunol (1999) 163:3957-62.
54. Deban L, Jarva H, Lehtinen MJ, Bottazzi B, Bastone A, Doni A, et al. Binding of the long pentraxin PTX3 to factor H: interacting domains and function in the regulation of complement activation. J Immunol (2008) 181:8433-40. doi:10.4049/jimmunol.181.12.8433.
55. Fox S, Ryan KA, Berger AH, Petro K, Das S, Crowe SE, et al. The role of C1q in recognition of apoptotic epithelial cells and inflammatory cytokine production by phagocytes during Helicobacter pylori infection. J Inflamm (Lond) (2015) 12:51. doi:10.1186/s12950-015-0098-8.
56. Stone MA, Mayberry JF, Baker R. Prevalence and management of inflammatory bowel disease: a cross-sectional study from central England. Eur J Gastroenterol Hepatol (2003) 15:1275-80. doi:10.1097/00042737-200312000-00004.
57. Van Limbergen J, Russell RK, Drummond HE, Aldhous MC, Round NK, Nimmo ER, et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology (2008) 135:1114-22. doi:10.1053/j.gastro.2008.06.081.
58. Bak-Romaniszyn L, Szala A, Sokolowska A, Mierzwa G, Czerwionka-Szaflarska M, Swierzko AS, et al. Mannan-binding lectin deficiency in pediatric patients with inflammatory bowel disease. Scand J Gastroenterol (2011) 46:1275-8. doi:10.3109/00365521.2011.594087.
59. Aittoniemi J, Pertovaara M, Hulkkonen J, Pasternack A, Hurme M, Laippala P, et al. The significance of mannan-binding lectin gene alleles in patients with primary Sjögren's syndrome. Scand J Rheumatol (2002) 31:362-5. doi:10.1080/030097402320817095.
60. Slade JD, Luskin AT, Gewurz H, Kraft SC, Kirsner JB, Zeitz HJ. Inherited deficiency of second component of complement and HLA haplotype A10, B18 associated with inflammatory bowel disease. Ann Intern Med (1978) 88:796-8. doi:10.7326/0003-4819-88-6-796.
61. Freeman HJ. Hereditary angioneurotic edema and familial Crohn's disease. Can J Gastroenterol (2000) 14:337-9.
62. Farkas H, Gyeney L, Nemesanszky E, Kaldi G, Kukan F, Masszi I, et al. Coincidence of hereditary angioedema (HAE) with Crohn's disease. Immunol Invest (1999) 28:43-53. doi:10.3109/08820139909022722.
63. Kolho KL, Paakkanen R, Lepistö AL, Wennerstom A, Meri S, Lokki ML. Novel associations between major histocompatibility complex and pediatric-onset inflammatory bowel disease. J Pediatr Gastroenterol Nutr (2015). doi:10.1097/MPG.0000000000000984.
64. Sandahl TD, Kelsen J, Dige A, Dahlerup JF, Agnholt J, Hvas CL, et al. The lectin pathway of the complement system is downregulated in Crohn's disease patients who respond to anti-TNF-alpha therapy. J Crohns Colitis (2014) 8:521-8. doi:10.1016/j.crohns.2013.11.007.
65. Diegelmann J, Czamara D, Le Bras E, Zimmermann E, Olszak T, Bedynek A, et al. Intestinal DMBT1 expression is modulated by Crohn's disease-associated IL23R variants and by a DMBT1 variant which influences binding of the transcription factors CREB1 and ATF-2. PLoS One (2013) 8:e77773. doi:10.1371/journal.pone.0077773.
66. Kim TH, Lee SH, Lee HM, Jung HH, Lee SH, Cho WS, et al. Increased expression of glycoprotein 340 in the ethmoid sinus mucosa of patients with chronic sinusitis. Arch Otolaryngol Head Neck Surg (2007) 133:1111-4. doi:10.1001/archotol.133.11.1111.
67. Renner M, Bergmann G, Krebs I, End C, Lyer S, Hilberg F, et al. DMBT1 confers mucosal protection in vivo and a deletion variant is associated with Crohn's disease. Gastroenterology (2007) 133:1499-509. doi:10.1053/j.gastro.2007.08.007.
68. Hamm CM, Reimers MA, McCullough CK, Gorbe EB, Lu J, Gu CC, et al. NOD2 status and human ileal gene expression. Inflamm Bowel Dis (2010) 16:1649-57. doi:10.1002/ibd.21208.
69. Muller H, End C, Weiss C, Renner M, Bhandiwad A, Helmke BM, et al. Respiratory deleted in malignant brain tumours 1 (DMBT1) levels increase during lung maturation and infection. Clin Exp Immunol (2008) 151:123-9. doi:10.1111/j.1365-2249.2007.03528.x.
70. Madsen J, Sorensen GL, Nielsen O, Tornoe I, Thim L, Fenger C, et al. A variant form of the human deleted in malignant brain tumor 1 (DMBT1) gene shows increased expression in inflammatory bowel diseases and interacts with dimeric trefoil factor 3 (TFF3). PLoS One (2013) 8:e64441. doi:10.1371/journal.pone.0064441.
71. Aamann L, Vestergaard EM, Gronbaek H. Trefoil factors in inflammatory bowel disease. World J Gastroenterol (2014) 20:3223-30. doi:10.3748/wjg.v20.i12.3223.